|
Mental Depression
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Among all candidate substrates, DPP4 displays highest affinity for NPY, an endogenous anxiolytic neurotransmitter that is suggested as a candidate biomarker in post-traumatic stress disorder (PTSD) and depression.
|
25635612 |
2015 |
|
Depressive disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Among all candidate substrates, DPP4 displays highest affinity for NPY, an endogenous anxiolytic neurotransmitter that is suggested as a candidate biomarker in post-traumatic stress disorder (PTSD) and depression.
|
25635612 |
2015 |
|
Mental Depression
|
0.310 |
Biomarker
|
disease |
BEFREE |
Six genes were identified as of interest for a follow-up, based on the strength of the association and based on the interest as potential candidate target for developing new treatment for depression: Solute Carrier Family 4 Member 10 (SLC4A10), Dipeptidyl Peptidase IV (DPP4), Dopamine Receptor D3 (DRD3), Zinc Finger Protein 80 (ZNF80), Nitric Oxide Synthase 2A (NOS2A) and Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1, Alpha (PPARGC1A).
|
21630437 |
2011 |
|
Mental Depression
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Six genes were identified as of interest for a follow-up, based on the strength of the association and based on the interest as potential candidate target for developing new treatment for depression: Solute Carrier Family 4 Member 10 (SLC4A10), Dipeptidyl Peptidase IV (DPP4), Dopamine Receptor D3 (DRD3), Zinc Finger Protein 80 (ZNF80), Nitric Oxide Synthase 2A (NOS2A) and Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1, Alpha (PPARGC1A).
|
21630437 |
2011 |
|
Depressive disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Six genes were identified as of interest for a follow-up, based on the strength of the association and based on the interest as potential candidate target for developing new treatment for depression: Solute Carrier Family 4 Member 10 (SLC4A10), Dipeptidyl Peptidase IV (DPP4), Dopamine Receptor D3 (DRD3), Zinc Finger Protein 80 (ZNF80), Nitric Oxide Synthase 2A (NOS2A) and Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1, Alpha (PPARGC1A).
|
21630437 |
2011 |
|
Depressive disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
Six genes were identified as of interest for a follow-up, based on the strength of the association and based on the interest as potential candidate target for developing new treatment for depression: Solute Carrier Family 4 Member 10 (SLC4A10), Dipeptidyl Peptidase IV (DPP4), Dopamine Receptor D3 (DRD3), Zinc Finger Protein 80 (ZNF80), Nitric Oxide Synthase 2A (NOS2A) and Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1, Alpha (PPARGC1A).
|
21630437 |
2011 |
|
Proteinuria
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
[Renal dipeptidylpeptidase IV excretion in drug-induced kidney changes].
|
2880436 |
1986 |
|
Rheumatoid Arthritis
|
0.190 |
Biomarker
|
disease |
BEFREE |
To evaluate the real-world effect of dipeptidyl peptidase-4 inhibitor (DPP4i) on the incidence of autoimmune diseases (AD), including rheumatoid arthritis (RA), inflammatory bowel diseases, multiple sclerosis and systemic lupus erythematosus.
|
30964554 |
2019 |
|
Rheumatoid Arthritis
|
0.190 |
GeneticVariation
|
disease |
BEFREE |
Compared with use of other antidiabetic drugs, use of DPP-4 inhibitors was not associated with an increased risk of rheumatoid arthritis (82 vs. 79 per 100,000/year; HR = 1.0; 95% CI = 0.8, 1.3), with no evidence of duration-response relation.
|
30028343 |
2018 |
|
Rheumatoid Arthritis
|
0.190 |
Biomarker
|
disease |
BEFREE |
Median cDPP4 was significantly lower in the RA group (P = 0.02), and SSc group (P = 0.002) compared with controls.
|
27990763 |
2018 |
|
Rheumatoid Arthritis
|
0.190 |
Biomarker
|
disease |
BEFREE |
DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case-Control Study.
|
29236221 |
2018 |
|
Rheumatoid Arthritis
|
0.190 |
AlteredExpression
|
disease |
BEFREE |
The current study evaluated the association of DPP-IV enzymatic activity and its gene expression with disease activity and bone erosion in rheumatoid arthritis.
|
30136129 |
2018 |
|
Rheumatoid Arthritis
|
0.190 |
Biomarker
|
disease |
BEFREE |
As DPP-IV/CD26 is associated to factors triggering RA in the lung and periodontal tissue, these results suggest that Anti-CD26 isotypes may participate in pathogenesis and may be useful as biomarkers for earlier diagnosis and/or precision medicine.
|
28599787 |
2017 |
|
Rheumatoid Arthritis
|
0.190 |
AlteredExpression
|
disease |
BEFREE |
Activity and expression of dipeptidyl peptidase IV on peripheral blood mononuclear cells in patients with early steroid and disease modifying antirheumatic drugs naïve rheumatoid arthritis.
|
27341562 |
2017 |
|
Rheumatoid Arthritis
|
0.190 |
Biomarker
|
disease |
BEFREE |
Evidence of epistatic interaction between DPP4 and CCR6 in patients with rheumatoid arthritis.
|
27587881 |
2016 |
|
Rheumatoid Arthritis
|
0.190 |
AlteredExpression
|
disease |
BEFREE |
We conclude that, according to their CD26 expression, different cell subsets could serve to monitor RA course, and an uncharacterized T helper CD26- subset, not targeted by therapies, should be monitored for early diagnosis.
|
26177310 |
2015 |
|
Rheumatoid Arthritis
|
0.190 |
GeneticVariation
|
disease |
GWASCAT |
Novel risk loci for rheumatoid arthritis in Han Chinese and congruence with risk variants in Europeans.
|
24782177 |
2014 |
|
Rheumatoid Arthritis
|
0.190 |
GeneticVariation
|
disease |
GWASDB |
Novel risk loci for rheumatoid arthritis in Han Chinese and congruence with risk variants in Europeans.
|
24782177 |
2014 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Neither GLP-1 receptor agonists nor DPP-4 inhibitors were associated with a significantly elevated or reduced risk of pancreatic cancer or for the totality of all malignant neoplasms.
|
31750601 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Modulation of platelet function by diabetes agents in addition to their hypoglycemic effects would contribute to cardiovascular protection Newly introduced antidiabetic drugs of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors may have anti-platelet effects, and in the case of SGLT2i and GLP-1RA may contribute to their proven cardiovascular benefit that has been shown clinically.
|
31612835 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
There have been a number of case reports and small clinical series reporting the potential association between dipeptidyl peptidase-4 inhibitors (DPPIs) for diabetes and the onset of bullous pemphigoid (BP).
|
31215644 |
2020 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase-4 inhibitors in treatment-naïve patients with type 2 diabetes in Japan.
|
31145536 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dipeptidyl peptidase-4 inhibitor (DPP-4-Is), a kind of drug used for the treatment of diabetes, is considered to prevent the degradation of substance P that suppresses the occurrence of dysphagia.
|
31822955 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on this evidence, dipeptidyl peptidase-4 inhibitors should be considered for hospitalized patients with type 2 diabetes and an algorithm for this is proposed.
|
31529777 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results may have direct translational implications as DPP4 inhibitors are already in clinical use for diabetes.This article is protected by copyright.All rights reserved.
|
31350829 |
2020 |